

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ARCH Venture Partners VIII, LLC</u> (Last) (First) (Middle) <u>C/O ARCH VENTURE PARTNERS</u> <u>8755 W. HIGGINS ROAD, SUITE 1025</u> (Street) <u>CHICAGO IL 60631</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Sienna Biopharmaceuticals, Inc. [SNNA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>08/01/2017</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/01/2017		C		2,538,641	A	(1)	2,538,641	I	See Footnote ⁽²⁾
Common Stock	08/01/2017		C		211,934	A	(1)	2,750,575	I	See Footnote ⁽²⁾
Common Stock	08/01/2017		C		563,072	A	(1)	563,072	I	See Footnote ⁽³⁾
Common Stock	08/01/2017		C		319,421	A	(1)	882,493	I	See Footnote ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A-3 Preferred Stock	(1)	08/01/2017		C			2,538,641	(1)	(4)	Common Stock	2,538,641	(1)	0	I	See Footnote ⁽²⁾
Series A-3 Preferred Stock	(1)	08/01/2017		C			563,072	(1)	(4)	Common Stock	563,072	(1)	0	I	See Footnote ⁽³⁾
Series B Preferred Stock	(1)	08/01/2017		C			211,934	(1)	(4)	Common Stock	211,934	(1)	0	I	See Footnote ⁽²⁾
Series B Preferred Stock	(1)	08/01/2017		C			319,421	(1)	(4)	Common Stock	319,421	(1)	0	I	See Footnote ⁽³⁾

1. Name and Address of Reporting Person*

[ARCH Venture Partners VIII, LLC](#)

(Last) (First) (Middle)

C/O ARCH VENTURE PARTNERS
8755 W. HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[ARCH Venture Partners VIII, L.P.](#)

(Last) (First) (Middle)

C/O ARCH VENTURE PARTNERS VIII, LLC
8755 W. HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[ARCH Venture Fund VIII, L.P.](#)

(Last) (First) (Middle)

C/O ARCH VENTURE PARTNERS VIII, LLC
8755 W. HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[ARCH Venture Fund VIII Overage, L.P.](#)

(Last) (First) (Middle)

C/O ARCH VENTURE PARTNERS VIII, LLC
8755 W. HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[BYBEE CLINTON](#)

(Last) (First) (Middle)

C/O ARCH VENTURE PARTNERS VIII, LLC
8755 W. HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*		
<u>CRANDELL KEITH</u>		
(Last)	(First)	(Middle)
C/O ARCH VENTURE PARTNERS VIII, LLC		
8755 W. HIGGINS ROAD, SUITE 1025		
(Street)		
CHICAGO	IL	60631
(City) (State) (Zip)		

Explanation of Responses:

- The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.
- The shares are directly held by ARCH Venture Fund VIII, L.P. ("ARCH VIII"). ARCH Venture Partners VIII, L.P. (the "GPLP"), as the sole general partner of ARCH VIII, may be deemed to beneficially own certain of the shares held by ARCH VIII. ARCH Venture Partners VIII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VIII. Keith Crandell and Clinton Bybee are managing directors of GPLLC, and as such may be deemed to beneficially own the shares held by ARCH VIII. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
- The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). GPLLC, as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. Keith Crandell and Clinton Bybee are managing directors of GPLLC, and as such may be deemed to beneficially own the shares held by ARCH Overage. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
- The expiration date is not relevant to the conversion of these securities.

<u>ARCH Venture Fund VIII, L.P. By: ARCH Venture Partners VIII, L.P. By: /s/Mark McDonnell, as Attorney-in- Fact for Keith Crandell, the Mngng Dir of ARCH Venture Partners VIII LLC, the GP of ARCH Venture Partners VIII, L.P., the GP of ARCH Venture Fund VIII</u>	<u>08/01/2017</u>
<u>ARCH Venture Fund VIII Overage, L.P. By: ARCH Venture Partners VIII, LLC By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, the Managing Director of ARCH Venture Partners VIII LLC, the GP of ARCH Venture Fund VIII Overage, L.P.</u>	<u>08/01/2017</u>
<u>ARCH Venture Partners VIII, L.P. By: ARCH Venture Partners VIII, LLC By: /s/ Mark McDonnell as Attorney- in-Fact for Keith Crandell, the Managing Director of ARCH Venture Partners VIII LLC, the GP of ARCH Venture Partners VIII, L.P.</u>	<u>08/01/2017</u>
<u>ARCH Venture Partners VIII, LLC By: /s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell, the Managing Director of ARCH Venture Partners VIII, LLC</u>	<u>08/01/2017</u>
<u>/s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell</u>	<u>08/01/2017</u>
<u>/s/ Mark McDonnell, as Attorney-in-Fact for Clinton Bybee</u>	<u>08/01/2017</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.